Related references
Note: Only part of the references are listed.BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
Jamshid S. Khorashad et al.
BLOOD (2013)
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
Simona Soverini et al.
BLOOD (2013)
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments
Erik Laurini et al.
MOLECULAR ONCOLOGY (2013)
Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
Karunakar Tanneeru et al.
PLOS ONE (2013)
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm
Don L. Gibbons et al.
CANCER (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations
Tingjun Hou et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Doriano Fabbro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells
J. Wu et al.
LEUKEMIA (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Computations of Standard Binding Free Energies with Molecular Dynamics Simulations
Yuqing Deng et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2009)
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Constantine S. Tam et al.
BLOOD (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
SGX393 inhibits the CML mutant Bcr-AblT3151 and preempts in vitro resistance when combined with nilotinib or dasatinib
Thomas O'Hare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Fusion tyrosine kinases: a result and cause of genomic instability
E. T. P. Penserga et al.
ONCOGENE (2007)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes et al.
CLINICAL CANCER RESEARCH (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
NJ Donato et al.
CANCER RESEARCH (2004)
Imatinib therapy in chronic myelogenous leukemia:: strategies to avoid and overcome resistance
A Hochhaus et al.
LEUKEMIA (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations
Y Duan et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2003)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
A myristoyl/phosphotyrosine switch regulates c-Abl
O Hantschel et al.
CELL (2003)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini et al.
LANCET ONCOLOGY (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance
W Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
On the calculation of entropy from covariance matrices of the atomic fluctuations
I Andricioaei et al.
JOURNAL OF CHEMICAL PHYSICS (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Share Paper
